Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB389IL-2

Cellular Immunology

Volumn 261, Issue 2, 2010, Pages 144-152

  Phillips, S Michael ^b   Bhopale, Mahendra K ^c   Hilliard, Brendan ^c   Zekavat, Seyed Ali ^b   Ali, Mohamad Anwar Ramadan ^b   Rostami, Abdolmohamad ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAB389IL 2; Experimental autoimmune encephalomyelitis; Interleukin 2 receptor; Multiple sclerosis

Indexed keywords

CD11B ANTIGEN; DA GLU53 B389 INTERLEUKIN 2 FUSION PROTEIN; DAB 389 INTERLEUKIN 2 [8-10] FUSION PROTEIN; DENILEUKIN DIFTITOX; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; MITOSIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; SPINAL CORD LESION; SPLEEN CELL;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DIPHTHERIA TOXIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MICE; MULTIPLE SCLEROSIS; RATS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SPINAL CORD; T-LYMPHOCYTES;

MURINAE; MUS; RATTUS;

EID: 77649182248     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.12.001     Document Type: Article

References (78)

1. Matsui M., Araya S., Wang H.Y., Matsushima K., Saida T. Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. J. Neurol. 2005, 252:908-915.
2. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., J Khoury S., Weiner H.L. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 2006, 177:4196-4202.
3. Ratts R.B., Karandikar N.J., Hussain R.Z., Choy J., Northrop S.C., Lovett-Racke A.E., Racke M.K. Phenotypic characterization of autoreactive T cells in multiple sclerosis. J. Neuroimmunol. 2005, 178:100-110.
4. Goverman J., Perchellet A., Huseby E.S. The role of CD8 (+) T cells in multiple sclerosis and its animal models. Curr. Drug Targets Inflamm. Allergy 2005, 4:239-245. (Review).
5. Duszczyszyn D.A., Beck J.D., Antel J., Bar-Or A., Lapierre Y., Gadag V., Haegert D.G. ltered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clin. Exp. Immunol. 2006, 439:305-313.
6. Haegele K.F., Stueckle C.A., Malin J.P., Sindern E. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J. Neuroimmunol. 2007, 183:168-174.
7. Stuve O., Marra C.M., Bar-Or A., Niino M., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Jerome K.R., Cook L., Grand'Maison F., Hemmer B., Monson N.L., Racke M.K. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 2006, 63:1383-1387.
8. Pettinelli C.B., McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J. Immunol. 1981, 127:1420-1423.
9. Fransson M.E., Liljenfeldt L.S., Fagius J., Tötterman T.H., Loskog A.S. The T-cell pool is anergized in patients with multiple sclerosis in remission. Immunology 2009, 126:92-101.
10. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
11. Kroenke M.A., Segal B.M. Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2007, 5:1685-1693.
12. Pastor S., Vaccaro C.G., Minguela A., Ober R.J., Ward E.S. Analyses of TCR clustering at the T cell-antigen-presenting cell interface and its impact on the activation of naive CD4+ T cells. Int. Immunol. 2006, 18:1615-1625.
13. Lavasani S., Dzhambazov B., Anderson M. Monoclonal antibody against T-cell receptor alpha beta induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2007, 65:39-47.
14. Liparoto S.F., Ciardelli T.L. Biosensor analysis of the interleukin-2 receptor complex. J. Mol. Recognit. 1999, 12:316-321.
15. Zmuidzinas A., Mamon H.J., Roberts T.M., Smith K.A. Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity increase through G1 and S in CD3-stimulated primary human T cells. Mol. Cell. Biol. 1991, 11:2794-2803.
16. Moon J.J., Rubio E.D., Martino A., Krumm A., Nelson B.H. A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J. Biol. Chem. 2004, 279:5520-5527.
17. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., Hoffmeyer A., van Deursen J., Sangster M.Y., Bunting K.D., Grosveld G.C., Ihle J.N. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999, 10:249-259.
18. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv. Immunol. 1998, 70:1-81.
19. Nakamura Y., Russell S.M., Mess S.A., Friedmann M., Erdos M., Francois C., Jacques Y., Adelstein S., Leonard W.J. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 1994, 369:330-333.
20. Nelson B.H., Lord J.D., Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994, 369:333-336.
21. Wang H.M., Smith K.A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J. Exp. Med. 1985, 166:1055-1069.
22. Gartner D., Hoff H., Gimsa U., Burmester G.R., Brunner-Weinzierl M.C. CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression. J. Neuroimmunol. 2006, 172:73-84.
23. Furtado G.C., Pina B., Tacke F., Gaupp S., van Rooijen N., Moran T.M., Randolph G.J., Ransohoff R.M., Chensue S.W., Raine C.S., Lira S.A. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. J. Immunol. 2006, 177:6871-6879.
24. Engelhardt B., Diamantstein T., Wekerle H. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 1989, 2:61-73.
25. Miller A., Hafler D.A., Weiner H.L. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. FASEB J. 1991, 11:2560-2566. (Review).
26. Padula S.J., Lingenheld E.G., Stabach P.R., Chou C.H., Kono D.H., Clark R.B. Identification of encephalitogenic V beta-4-bearing T cells in SJL mice. Further evidence for the V region disease hypothesis?. J. Immunol. 1991, 146:879-883.
27. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., Lafaille J.J. Interleukin 2 signaling is required for CD4 (+) regulatory T cell function. J. Exp. Med. 2002, 196:851-857.
28. Powell N.D., Papenfuss T.L., McClain M.A., Gienapp I.E., Shawler T.M., Satoskar A.R., Whitacre C.C. Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:5611-5614.
29. Merkler D., Boscke R., Schmelting B., Czeh B., Fuchs E., Bruck W., Stadelmann C. Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol. 2006, 16:117-123.
30. Wheeler R.D., Zehntner S.P., Kelly L.M., Bourbonniere L., Owens T. Elevated interferon gamma expression in the central nervous system of tumour necrosis factor receptor 1-deficient mice with experimental autoimmune encephalomyelitis. Immunology 2006, 118:527-538.
31. Williams D.P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F., Strom T.B., Murphy J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987, 1:493-498.
32. Williams D.P., Wen Z., Watson R.S., Boyd J., Strom T.B., Murphy J.R. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J. Biol. Chem. 1990, 265:20673-20677.
33. Bacha P., Williams D.P., Waters C., Williams J.M., Murphy J.R., Strom T.B. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J. Exp. Med. 1988, 167:612-622.
34. Waters C.A., Schimke P.A., Snider C.E., Itoh K., Smith K.A., Nichols J.C., Strom T.B., Murphy J.R. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 1990, 20:785-791.
35. Balcer L.J., McIntosh K.R., Nichols J.C., Drachman D.B. Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies. J. Neuroimmunol. 1991, 31:115-122.
36. Kawakami K., Nakajima O., Morishita R., Nagai R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. Scientific World J. 2006, 6:781-790. (Review).
37. Hayashi R.J., Kanagawa O. Requirement of high affinity IL-2-IL-2R interaction for T cell anergy induction. Int. Immunol. 2006, 18:645-651.
38. Pacheco-Silva A., Bastos M.G., Muggia R.A., Pankewycz O., Nichols J., Murphy J.R., Strom T.B., Rubin-Kelley V.E. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur. J. Immunol. 1992, 22:697-702.
39. Bacha P., Forte S.E., Perper S.J., Trentham D.E., Nichols J.C. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis. Eur. J. Immunol. 1992, 22:1673-1679.
40. Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990, 265:11885-11889.
41. Walz G., Zanker B., Brand K., Waters C., Genbauffe F., Zeldis J.B., Murphy J.R., Strom T.B. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc. Natl. Acad. Sci. USA 1989, 86:9485-9488.
42. Sewell K.L., Parker K.C., Woodworth T.G., Reuben J., Swartz W., Trentham D.E. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum. 1993, 36:1223-1233.
43. Woodworth T.G. Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus. Clin. Exp. Rheumatol. 1993, 11(Suppl. 8):S177-S180.
44. vanderSpek J.C., Sutherland J.A., Ratnarathorn M., Howland K., Ciardelli T.L., Murphy J.R. DAB389 interleukin-2 receptor binding domain mutations. Cytotoxic probes for studies of ligand-receptor interactions. J. Biol. Chem. 1996, 271:12145-12149.
45. Saleh M.N., LeMaistre C.F., Kuzel T.M., Foss F., Platanias L.C., Schwartz G., Ratain M., Rook A., Freytes C.O., Craig F., Reuben J., Sams M.W., Nichols J.C. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J. Am. Acad. Dermatol. 1998, 39:63-73.
46. Foss F.M. DAB (389) IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma 2000, 1:110-116. (Review).
47. Duvic M., Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008, 4:457-469. (Review).
48. Holzman D.C. Whatever happened to immunotoxins? Research, and hope, are still alive. J. Natl. Cancer Inst. 2009, 101:624-625.
49. Martin A., Gutierrez E., Muglia J., McDonald C.J., Guzzo C., Gottlieb A., Pappert A., Garland W.T., Bagel J., Bacha P. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol. 2001, 45:871-881.
50. Ramadan M.A., Gabr N.S., Bacha P., Gunzler V., Phillips S.M. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2: studies of in vitro and in vivo efficacy. Cell. Immunol. 1995, 166:217-226.
51. Phillips S.M., Bhopale M.K., Constantinescu C.S., Ciric B., Hilliard B., Ventura E., Lavi E., Rostami A. Effect of DAB (389) IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J. Neurol. Sci. 2007, 263:59-69.
52. Constantinescu C.S., Hilliard B., Wysocka M., Ventura E.S., Bhopale M.K., Trinchieri G., Rostami A.M. IL-12 reverses the suppressive effect of the CD40 ligand blockade experimental autoimmune encephalomyelitis (EAE). J. Neurol. Sci. 1999, 171:60-64.
53. Beraud E., Lorberboum-Galski H., Chan C.C., FitzGerald D., Pastan I., Nussenblatt R.B. Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. Cell. Immunol. 1991, 133:379-389.
54. Rose J.W., Lorberboum-Galski H., Fitzgerald D., McCarron R., Hill K.E., Townsend J.J., Pastan I. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 1991, 32:209-217.
55. Bastos M.G., Pankewycz O., Rubin-Kelley V.E., Murphy J.R., Strom T.B. Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones. J. Immunol. 1990, 145:3535-3539.
56. Sun D., Wilson D.B., Cao L., Whitaker J.N. The role of regulatory T cells in Lewis rats resistant to EAE. J. Neuroimmunol. 1998, 81:177-183.
57. Perrin P.J., Phillips R.J., Phillips S.M. The molecular basis of granuloma formation in schistosomiasis. IV. T cell-derived suppressor-inducer and suppressor-effector factor reactivities are regulated by a TCR beta chain analog. Cell. Immunol. 1989, 124:345-358.
58. Jiang H., Braunstein N.S., Yu B., Winchester R., Chess L. CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc. Natl. Acad. Sci. USA 2001, 98:6301-6306.
59. Elliott J.I., Douek D.C., Altmann D.M. Mice lacking alpha beta + T cells are resistant to the induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1996, 70:139-144.
60. Gao Y.L., Rajanm A.J., Raine C.S., Brosnan C.F. Gammadelta T cells express activation markers in the central nervous system of mice with chronic-relapsing experimental autoimmune encephalomyelitis. J. Autoimmun. 2001, 17:261-271.
61. Juedes A.E., Ruddle N.H. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. 2001, 166:5168-5175.
62. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
63. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
64. Mycko M.P., Waldner H., Anderson D.E., Bourcier K.D., Wucherpfennig K.W., Kuchroo V.K., Hafler D.A. Cross-reactive TCR responses to self antigens presented by different MHC class II molecules. J. Immunol. 2004, 173:1689-1698.
65. Bullard D.C., Hu X., Schoeb T.R., Axtell R.C., Raman C., Barnum S.R. Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:6327-6333.
66. Bullard D.C., Hu X., Adams J.E., Schoeb T.R., Barnum S.R. p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. Am. J. Pathol. 2007, 170:2001-2008.
67. Murzenok P.P., Matusevicius D., Freedman M.S. Gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clin. Immunol. 2002, 1039:309-316.
68. Ponomarev E.D., Novikova M., Yassai M., Szczepanik M., Gorski J., Dittel B.N. Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2004, 173:1587-1595.
69. Ponomarev E.D., Shriver L.P., Maresz K., Dittel B.N. Microglial cell activation and proliferation proceeds the onset of CNS autoimmunity. J. Neurosci. Res. 2005, 81:374-389.
70. Szalai A.J., Hu X., Raman C., Barnum S.R. Requirement of the Fc receptor common gamma-chain for gamma delta T cell-mediated promotion of murine experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2005, 35:3487-3492.
71. Jensen M.A., Dayal A., Arnason B.G. Cytokine secretion by delta gamma and alpha beta T cells in monophasic experimental autoimmune encephalomyelitis. J. Autoimmun. 1999, 12:73-80.
72. Ponomarev E.D., Dittel B.N. Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J. Immunol. 2005, 174:4678-4687.
73. Wong B.Y., Ma Y., Fitzwilson R., Dang N.H. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. Am. J. Hematol. 2008, 83:596-598.
74. Rasku M.A., Clem A.L., Telang S., Taft B., Gettings K., Gragg H., Cramer D., Lear S.C., McMasters K.M., Miller D.M., Chesney J. Transient T cell depletion causes regression of melanoma metastases. J. Trans. Med. 2008, 11:6-12.
75. Zalom M., Lill M., Lukic D., Balzer B.L., Lim S. Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma. Leuk. Lymphoma 2009, 50:124-126.
76. Litzinger M.T., Fernando R., Curiel T.J., Grosenbach D.W., Schlom J., Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-3201.
77. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Bäckström B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., Oukka M., Kuchroo V.K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007, 13:423-431.
78. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006, 116:1317-1326.